IOVANCE BIOTHERAPEUTICS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $263.5M | $164.1M | $1.2M | — | — |
| Cost of revenue | $173.2M | $93.2M | $1.0M | — | — |
| Research and development | $300.3M | $276.2M | $333.2M | $294.8M | $259.0M |
| Operating expenses | — | — | — | $398.9M | $342.7M |
| Operating income | -$403.4M | -$395.3M | -$460.6M | -$398.9M | -$342.7M |
| Pretax income | -$393.0M | -$375.0M | -$447.5M | -$395.9M | -$342.3M |
| Income tax expense | -$2.1M | -$2.8M | -$3.5M | $0 | $0 |
| Net income | -$391.0M | -$372.2M | -$444.0M | -$395.9M | -$342.3M |
| Balance Sheet | |||||
| Cash and equivalents | $163.1M | $115.7M | $114.9M | $231.7M | $78.2M |
| Current assets | $442.7M | $457.0M | $307.8M | $479.1M | $508.0M |
| Total assets | $913.2M | $910.4M | $780.4M | $664.0M | $777.3M |
| Current liabilities | $138.4M | $122.3M | $110.3M | $91.5M | $89.2M |
| Total liabilities | $214.6M | $200.0M | $195.7M | $164.3M | $155.7M |
| Stockholders' equity | $698.6M | $710.4M | $584.6M | $499.6M | $621.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$302.4M | -$353.0M | -$361.8M | -$292.8M | -$227.9M |
| Depreciation and amortization | $12.9M | $11.3M | $11.6M | $9.3M | $3.1M |
| Stock-based compensation | $61.6M | $109.6M | $62.6M | $84.0M | $69.8M |
| Capital expenditure | $33.8M | $11.1M | $22.3M | $20.4M | $37.6M |
| Free cash flow | -$336.2M | -$364.0M | -$384.1M | -$313.2M | -$265.5M |
| Impairments | — | $7.4M | — | $397,000 | $0 |
Shares outstanding 446.5M · Free float 84.4%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.